Log In
BCIQ
Print this Print this
 

HB-101

  Manage Alerts
Collapse Summary General Information
Company Hookipa Biotech AG
DescriptionBivalent vaccine against CMV that uses Vaxwave technology vectors to express CMV pp65 (UL83) and truncated CMV glycoprotein B
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83) ; Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationCytomegalovirus (CMV)
Indication DetailsVaccine against CMV infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today